Physician profile
James Christopher Botta
NPI 1669851887
$1,885.12
in general payments reported to CMS, 2019-2025
11 companies · $424 in 2025
The $424 reported for 2025 was more than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $184 · 2023: $963 · 2024: $314 · 2025: $424.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,701.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,701.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Integra Lifesciences Corporation | $1,576.54 | 2022-2025 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Tela Bio, INC. | $66.90 | 2025 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Chiesi USA, INC. | $51.43 | 2024-2025 | Cleviprex |
| Acera Surgical, INC. | $42.84 | 2024 | Restrata Wound Matrix |
| Convatec INC. | $26.40 | 2024 | |
| Haemonetics Corporation | $24.44 | 2023 | Teg6s Hemostasis System |
| Kerecis Limited | $23.97 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Edwards Lifesciences Corporation | $19.84 | 2023 | |
| Mesh Suture INC | $18.31 | 2025 | |
| Melinta Therapeutics, LLC | $17.66 | 2025 | Rezzayo |
| Musculoskeletal Transplant Foundation INC. | $16.79 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Botta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.